Related Experiment Video
Updated: May 20, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Prognostic value of CA125 in diffuse large B-cell lymphoma.
Jie Zhang1, Yijing Jiang2, Long Chen3
1Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.
Serum carbohydrate antigen 125 (CA125) levels at diagnosis predict prognosis in diffuse large B-cell lymphoma (DLBCL). Elevated CA125 indicates poorer survival outcomes for DLBCL patients.
Area of Science:
- Oncology
- Hematology
- Clinical Biomarkers
Background:
- Carbohydrate antigen 125 (CA125) is a tumor biomarker for solid neoplasms.
- Serum CA125 has shown correlation with prognosis in non-Hodgkin's lymphoma.
Purpose of the Study:
- To investigate the clinical significance of CA125 in diffuse large B-cell lymphoma (DLBCL).
Main Methods:
- Retrospective analysis of 315 newly diagnosed DLBCL patients.
- Correlation analysis of serum CA125 with clinicopathological parameters.
- Kaplan-Meier survival analysis, Cox proportional hazards model, and immunohistochemistry.
Main Results:
- Elevated serum CA125 (26% of patients) associated with poor performance, advanced stage, B symptoms, bulky mass, effusion, high IPI, elevated LDH, and low albumin.
- Elevated CA125 correlated with shorter progression-free survival (PFS) and overall survival (OS).
- CA125, cell of origin, IPI, and albumin were independent prognostic factors for OS and PFS; no CA125 expression found in DLBCL tissues.
Conclusions:
- Serum CA125 at initial diagnosis is a significant predictor of prognosis in DLBCL patients.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
